New Three-Drug cocktail aims to tackle tough leukemia
NCT ID NCT05657639
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of three drugs—venetoclax, cladribine, and low-dose cytarabine—in 68 adults aged 16-70 with acute myeloid leukemia that has returned or not responded to prior treatment. The goal is to see if this cocktail can shrink or eliminate leukemia cells better than standard therapy. Participants are randomly assigned to receive either the new combo or a standard regimen.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax, cladribine, and low-dose cytarabine (CAV regimen)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat acute myeloid leukemia that has come back or not responded to standard therapy.
What could go wrong
This is an early phase 2 trial with only 68 participants, so results may not apply to everyone. The combination may cause side effects like low blood counts or infections, and it may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••